Rapid Dose Therapeutics Corp. (RDTCF)
USD 0.18
(2150.0%)
USD 0.18
(2150.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -3.02 Million CAD | -3.66% |
| 2023 | -2.91 Million CAD | 17.32% |
| 2022 | -3.52 Million CAD | -142.99% |
| 2021 | -987.22 Thousand CAD | 79.0% |
| 2020 | -7.31 Million CAD | 39.4% |
| 2019 | -11.4 Million CAD | -22681.22% |
| 2018 | -50.07 Thousand CAD | -6.33% |
| 2017 | -47.09 Thousand CAD | 8.98% |
| 2016 | -51.74 Thousand CAD | 49.29% |
| 2015 | -102.03 Thousand CAD | -164.3% |
| 2014 | -38.6 Thousand CAD | -251.53% |
| 2013 | 25.47 Thousand CAD | 137.62% |
| 2012 | -67.72 Thousand CAD | 15.3% |
| 2011 | -79.95 Thousand CAD | -1074.96% |
| 2010 | -6805.00 CAD | -101.39% |
| 2009 | -3379.00 CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -725.65 Thousand CAD | -74.35% |
| 2024 FY | - CAD | 15.55% |
| 2024 Q4 | -980.17 Thousand CAD | -35.07% |
| 2024 Q2 | -416.21 Thousand CAD | -22.15% |
| 2024 Q1 | -318.65 Thousand CAD | 61.19% |
| 2023 Q4 | -878.07 Thousand CAD | -109.24% |
| 2023 Q2 | -758.18 Thousand CAD | 12.06% |
| 2023 Q3 | -419.65 Thousand CAD | 44.65% |
| 2023 Q1 | -862.11 Thousand CAD | 70.09% |
| 2023 FY | - CAD | 17.32% |
| 2022 Q3 | -603.14 Thousand CAD | -71.01% |
| 2022 FY | - CAD | -142.99% |
| 2022 Q4 | -2.88 Million CAD | -377.88% |
| 2022 Q1 | 303.25 Thousand CAD | 150.43% |
| 2022 Q2 | -352.7 Thousand CAD | -216.31% |
| 2021 Q3 | -311.94 Thousand CAD | -274.3% |
| 2021 Q1 | -265.69 Thousand CAD | 56.63% |
| 2021 Q4 | -601.33 Thousand CAD | -92.77% |
| 2021 Q2 | -83.34 Thousand CAD | 68.63% |
| 2021 FY | - CAD | 79.0% |
| 2020 Q3 | -2.41 Million CAD | -346.68% |
| 2020 FY | - CAD | 39.4% |
| 2020 Q1 | -3.18 Million CAD | 66.83% |
| 2020 Q2 | -541.18 Thousand CAD | 83.02% |
| 2020 Q4 | -612.59 Thousand CAD | 74.66% |
| 2019 Q4 | -9.6 Million CAD | -925.86% |
| 2019 FY | - CAD | -22681.22% |
| 2019 Q1 | -289.57 Thousand CAD | 76.33% |
| 2019 Q2 | -491.94 Thousand CAD | -69.89% |
| 2019 Q3 | -936.52 Thousand CAD | -90.37% |
| 2018 Q3 | -19.37 Thousand CAD | 27.59% |
| 2018 Q1 | -6384.00 CAD | -61.87% |
| 2018 Q2 | -26.76 Thousand CAD | -319.2% |
| 2018 FY | - CAD | -6.33% |
| 2018 Q4 | -1.22 Million CAD | -6213.5% |
| 2017 Q4 | -3944.00 CAD | 69.64% |
| 2017 Q3 | -12.98 Thousand CAD | 21.17% |
| 2017 Q2 | -16.47 Thousand CAD | -823.14% |
| 2017 FY | - CAD | 8.98% |
| 2017 Q1 | -1785.00 CAD | 89.47% |
| 2016 Q4 | -16.94 Thousand CAD | -42.69% |
| 2016 FY | - CAD | 49.29% |
| 2016 Q3 | -11.87 Thousand CAD | 18.48% |
| 2016 Q2 | -14.57 Thousand CAD | -69.02% |
| 2016 Q1 | -8621.00 CAD | -9.28% |
| 2015 FY | - CAD | -164.3% |
| 2015 Q3 | -17.83 Thousand CAD | 78.99% |
| 2015 Q2 | -84.91 Thousand CAD | -786.12% |
| 2015 Q1 | -9583.00 CAD | -216.58% |
| 2015 Q4 | -7889.00 CAD | 55.77% |
| 2014 Q2 | -18.58 Thousand CAD | -1789.02% |
| 2014 Q3 | 885.00 CAD | 104.76% |
| 2014 Q4 | -3027.00 CAD | -442.03% |
| 2014 Q1 | -984.00 CAD | 89.8% |
| 2014 FY | - CAD | -251.53% |
| 2013 Q4 | -9645.00 CAD | 14.32% |
| 2013 FY | - CAD | 137.62% |
| 2013 Q1 | -32.98 Thousand CAD | -94.83% |
| 2013 Q2 | -21.51 Thousand CAD | 34.76% |
| 2013 Q3 | -11.25 Thousand CAD | 47.69% |
| 2012 Q1 | -7582.00 CAD | 38.6% |
| 2012 Q2 | -36.89 Thousand CAD | -386.65% |
| 2012 Q3 | -5105.00 CAD | 86.16% |
| 2012 Q4 | -16.92 Thousand CAD | -231.62% |
| 2012 FY | - CAD | 15.3% |
| 2011 Q3 | -10.89 Thousand CAD | 23.08% |
| 2011 Q4 | -12.34 Thousand CAD | -13.39% |
| 2011 FY | - CAD | -1074.96% |
| 2011 Q1 | -7050.00 CAD | 86.91% |
| 2011 Q2 | -14.15 Thousand CAD | -100.82% |
| 2010 Q3 | -4886.00 CAD | -142.0% |
| 2010 Q1 | -1225.00 CAD | 40.1% |
| 2010 FY | - CAD | -101.39% |
| 2010 Q4 | -53.86 Thousand CAD | -1002.37% |
| 2010 Q2 | -2019.00 CAD | -64.82% |
| 2009 Q4 | -2045.00 CAD | 54.72% |
| 2009 Q3 | -4516.00 CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | 20.821% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 95.742% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1164.786% |
| SQZ Biotechnologies Company | -64.14 Million USD | 95.284% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -14.381% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 82.586% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.216% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -96.917% |
| Marizyme, Inc. | -34.28 Million USD | 91.177% |
| Genus plc | 73.7 Million USD | 104.104% |
| Pharming Group N.V. | 9.87 Million USD | 130.624% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -103.356% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 14.724% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 65.518% |
| ContraFect Corporation | -64.99 Million USD | 95.346% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -115.774% |
| IMV Inc. | -35.52 Million USD | 91.485% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -30.162% |
| ONE Bio Corp. | 13.61 Million USD | 122.219% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 93.728% |
| Mesoblast Limited | -62.38 Million USD | 95.152% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -483.874% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 184.679% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.784% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -378.29% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -32.403% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 48.983% |
| Biomind Labs Inc. | -1.03 Million USD | -192.372% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -4.578% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 57.763% |
| Skye Bioscience, Inc. | -13.54 Million USD | 77.673% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 45084.176% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 54.25% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -11998.944% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 33.173% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 22.13% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 80.94% |
| Accustem Sciences Inc. | -3.74 Million USD | 19.263% |
| EV Biologics, Inc. | -1.26 Million USD | -138.707% |
| Q BioMed Inc. | -617.62 Thousand USD | -389.734% |
| GB Sciences, Inc. | -1.41 Million USD | -113.027% |
| Alpha Cognition Inc. | -9.7 Million USD | 68.835% |
| CSL Limited | 4.78 Billion USD | 100.063% |
| Agentix Corp. | -1.37 Million USD | -120.501% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 92.369% |
| Enzolytics Inc. | -2.12 Million USD | -42.54% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -11.74 Million USD | 74.24% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 1.25% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -20.895% |
| argenx SE | -216.02 Million USD | 98.6% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 94.534% |
| HST Global, Inc. | -5303.00 USD | -56938.205% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 348.54% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -47.046% |
| Halberd Corporation | -74.27 Thousand USD | -3972.128% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 134.163% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 898.412% |
| Zenith Capital Corp. | -8.6 Million USD | 64.853% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -101.796% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -23.637% |
| AVAX Technologies, Inc. | -6.11 Million USD | 50.517% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1618.362% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -57.464% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -17262.585% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -192.302% |
| Helix BioMedix, Inc. | -1.04 Million USD | -189.085% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -72.842% |
| Kadimastem Ltd | -2.62 Million USD | -15.255% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 59.957% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1570.313% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 833.655% |
| Cell Source, Inc. | -4.27 Million USD | 29.205% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -723.683% |
| Regen BioPharma, Inc. | 1.46 Million USD | 306.332% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -222.828% |
| Affymax, Inc. | -14.29 Million USD | 78.841% |
| Mobile Lads Corp. | -2.24 Million USD | -34.963% |
| Itoco Inc. | -1.86 Million USD | -61.838% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -696.78% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -171.034% |
| International Stem Cell Corporation | 202 Thousand USD | 1597.394% |
| CytoDyn Inc. | -18.02 Million USD | 83.223% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3727.375% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -24634.124% |
| Qrons Inc. | -40.08 Thousand USD | -7446.558% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -522.786% |
| SYBLEU INC | -141.57 Thousand USD | -2036.551% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 673.483% |
| Rebus Holdings, Inc. | -951 Thousand USD | -218.058% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -184.812% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5646.079% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -22.86% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 91.567% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -6621.636% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -10.472% |
| Neutra Corp. | -181.24 Thousand USD | -1568.847% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 84.996% |
| PureTech Health plc | -11.62 Million USD | 73.985% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 84.995% |
| IXICO plc | -707 Thousand USD | -327.827% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 60.641% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 93.744% |
| CSL Limited | 4.73 Billion USD | 100.064% |
| Cellectis S.A. | -92.63 Million USD | 96.735% |